相似文献
1
The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial.
Br J Gen Pract. 2006 Dec;56(533):938-44.
2
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9.
3
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
BJU Int. 2008 Apr;101(7):847-52. doi: 10.1111/j.1464-410X.2008.07458.x.
4
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.
5
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
N Engl J Med. 1998 Feb 26;338(9):557-63. doi: 10.1056/NEJM199802263380901.
6
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.
7
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
J Urol. 2006 Sep;176(3):1051-6. doi: 10.1016/j.juro.2006.04.044.
8
An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
BJU Int. 2008 Jan;101(2):197-202. doi: 10.1111/j.1464-410X.2007.07320.x. Epub 2007 Nov 13.
9
BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
BJU Int. 2008 Mar;101 Suppl 3:17-21. doi: 10.1111/j.1464-410X.2008.07497.x.
10
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10.
引用本文的文献
1
How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials.
Br J Gen Pract. 2010 Jul;60(576):e305-18. doi: 10.3399/bjgp10X514819.
本文引用的文献
1
Guideline for the primary care management of male lower urinary tract symptoms.
BJU Int. 2004 May;93(7):985-90. doi: 10.1111/j.1464-410X.2004.04765.x.
2
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Urology. 2004 Apr;63(4):709-15. doi: 10.1016/j.urology.2004.01.001.
3
Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
JAMA. 2003 Sep 24;290(12):1624-32. doi: 10.1001/jama.290.12.1624.
4
Lower urinary tract symptoms of men seeking medical care--comparison of symptoms found in the clinical setting and in a community study.
Urology. 2003 Aug;62(2):266-72. doi: 10.1016/s0090-4295(03)00252-8.
5
AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.
J Urol. 2003 Aug;170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.
6
Tamsulosin for benign prostatic hyperplasia.
Cochrane Database Syst Rev. 2003(1):CD002081. doi: 10.1002/14651858.CD002081.
7
Terazosin for benign prostatic hyperplasia.
Cochrane Database Syst Rev. 2002(4):CD003851. doi: 10.1002/14651858.CD003851.
8
The appropriateness of treatment of benign prostatic hyperplasia: a comparison of Dutch and multinational criteria.
Health Policy. 2001 Jul;57(1):45-56. doi: 10.1016/s0168-8510(01)00127-0.
9
Who should be treated and how? Evidence-based medicine in symptomatic BPH.
Eur Urol. 1999;36 Suppl 3:40-51. doi: 10.1159/000052348.
10
Management of symptomatic BPH in the UK: who is treated and how?
Eur Urol. 1999;36 Suppl 3:33-9. doi: 10.1159/000052347.
Zotero 插件